Published in Pharma Law Weekly, December 16th, 2008
On December 3, a Health Canada expert advisory panel will meet to decide on aprotinin use. The study is being early released in advance of the meeting.
The study, a systematic review of 49 randomized trials, compared aprotinin with lysine analogues. It includes new information from The Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) study...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.